Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] Assessed on the Cardiac Na+-Ca2+ Exchanger, NCX1.1

Candace Lee, Neeraj S. Visen, Naranjan S. Dhalla, Hoa Dinh Le, Michael Isaac, Platon Choptiany, Gil Gross, Alexander Omelchenko, Toshio Matsuda, Akemichi Baba, Kenzo Takahashi, Mark Hnatowich and Larry V. Hryshko
Journal of Pharmacology and Experimental Therapeutics November 2004, 311 (2) 748-757; DOI: https://doi.org/10.1124/jpet.104.070805
Candace Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeraj S. Visen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naranjan S. Dhalla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hoa Dinh Le
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Isaac
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Platon Choptiany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gil Gross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Omelchenko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshio Matsuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akemichi Baba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenzo Takahashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Hnatowich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry V. Hryshko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline) has recently been described as a potent and selective inhibitor of Na+-Ca2+ exchange in cardiac, neuronal, and renal preparations. The inhibitory effects of SEA0400 were investigated on the cloned cardiac Na+-Ca2+ exchanger, NCX1.1, expressed in Xenopus laevis oocytes to gain insight into its inhibitory mechanism. Na+-Ca2+ exchange currents were measured using the giant excised patch technique using conditions to evaluate both inward and outward currents. SEA0400 inhibited outward Na+-Ca2+ exchange currents with high affinity (IC50 = 78 ± 15 and 23 ± 4 nM for peak and steady-state currents, respectively). Considerably less inhibitory potency (i.e., micromolar) was observed for inward currents. The inhibitory profile was reexamined after proteolytic treatment of excised patches with α-chymotrypsin, a procedure that eliminates ionic regulatory mechanisms. After this treatment, an IC50 value of 1.2 ± 0.6 μM was estimated for outward currents, whereas inward currents became almost insensitive to SEA0400. The inhibitory effects of SEA0400 on outward exchange currents were evident at both high and low concentrations of regulatory Ca2+, although distinct features were noted. SEA0400 accelerated the inactivation rate of outward currents. Based on paired pulse experiments, SEA0400 altered the recovery of exchangers from the Na+i-dependent inactive state, particularly at higher regulatory Ca2+i concentrations. Finally, the inhibitory potency of SEA0400 was strongly dependent on the intracellular Na+ concentration. Our data confirm that SEA0400 is the most potent inhibitor of the cardiac Na+-Ca2+ exchanger described to date and provide a reasonable explanation for its apparent transport mode selectivity.

Footnotes

  • This study was supported by operating grants from the Heart and Stroke Foundation of Manitoba and the Canadian Institutes of Health Research (CIHR) and by a Canada Research Chair Award (to L.V.H.). C.L. was supported by a CIHR Postdoctoral Fellowship Award and the Tailored Advanced Collaborative Training in Cardiovascular Science for Research Fellows (TACTICS) Partnership Program of the CIHR and the Heart and Stroke Foundation.

  • doi:10.1124/jpet.104.070805.

  • ABBREVIATIONS: NHE, Na+-H+ exchanger; [Ca2+]i, intracellular Ca2+; KB-R7943, 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate; SEA0400, 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline; MES, 4-morpholineethanesulfonic acid; TEA, tetraethylammonium; MOPS, 4-morpholinepropanesulfonic acid; λ, rate of current decay; FSS, extent of current inactivation.

    • Received April 29, 2004.
    • Accepted July 1, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 311 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 311, Issue 2
1 Nov 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] Assessed on the Cardiac Na+-Ca2+ Exchanger, NCX1.1
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] Assessed on the Cardiac Na+-Ca2+ Exchanger, NCX1.1

Candace Lee, Neeraj S. Visen, Naranjan S. Dhalla, Hoa Dinh Le, Michael Isaac, Platon Choptiany, Gil Gross, Alexander Omelchenko, Toshio Matsuda, Akemichi Baba, Kenzo Takahashi, Mark Hnatowich and Larry V. Hryshko
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 748-757; DOI: https://doi.org/10.1124/jpet.104.070805

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] Assessed on the Cardiac Na+-Ca2+ Exchanger, NCX1.1

Candace Lee, Neeraj S. Visen, Naranjan S. Dhalla, Hoa Dinh Le, Michael Isaac, Platon Choptiany, Gil Gross, Alexander Omelchenko, Toshio Matsuda, Akemichi Baba, Kenzo Takahashi, Mark Hnatowich and Larry V. Hryshko
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 748-757; DOI: https://doi.org/10.1124/jpet.104.070805
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin Synthesis in Red Blood Cells
  • Exosomal miRNAs drive thrombosis in COVID-19
  • mitochondrial miRs in Fabry disease
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics